Blogs

Franny White

OHSU researchers studying COVID-19 are encouraged to access data from the records of more than 50,000 coronavirus-positive patients that are part of the new National COVID Cohort Collaborative (N3C) data platform.

Christopher P. Austin, MD - Director, National Center for Advancing Translational Sciences

CD2H has galvanized an entire community to address the multitude of issues surrounding data acquisition, harmonization, and analytics.

Christopher P. Austin, MD - Director, National Center for Advancing Translational Sciences

One of the many difficulties of COVID-19 is knowing who has had it. Not everyone who is infected develops symptoms, and not everyone who has symptoms gets a diagnostic test for the presence of SARS-CoV-2, the virus that causes COVID-19. But knowing how many people in a community have been infected is critical for understanding the spread of the virus and how long people may remain protected after infection.

Amy (Nordo) Cramer, MMCi, RN, CPHQ - Co-chair of the Vulcan Steering Committee and serves in global product strategic partnerships at Pfizer

HL7 recently announced the launch of its newest FHIR AcceleratorProject Vulcan, which seeks to use its widely recognized data exchange standards to help health care researchers more effectively acquire, exchange and use data in translational and clinical research.

Mike G. Kurilla, MD, PhD - Director of NCATS Clinical Innovation

As the COVID-19 pandemic continues to rampage across the globe and now some nations previously lauded for their infection control practice are seeing a resurgence, along with emerging science suggesting not only a very low infectious dose, but also efficient asymptomatic transmission, the focus on COVID interventions both treatment and prevention is heating up.

Christopher P. Austin, MD - Director, National Center for Advancing Translational Sciences

A bedrock principle at NCATS is that translation is complete only when interventions reach and benefit all the individuals and communities that need them. This critical step of the translational process, referred to as Dissemination and Implementation (D&I), often is stalled by a lack of inclusion in clinical trials, hindering the development of effective new interventions and preventing existing ones from reaching the people for whom they were created.